[{"orgOrder":0,"company":"KeifeRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Neurology","graph2":"Phase II","graph3":"KeifeRx","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"KeifeRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KeifeRx \/ Undisclosed"},{"orgOrder":0,"company":"KeifeRx","sponsor":"KeifeRx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"KFRX03","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"KeifeRx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"KeifeRx \/ KeifeRx","highestDevelopmentStatusID":"5","companyTruncated":"KeifeRx \/ KeifeRx"}]

Find Clinical Drug Pipeline Developments & Deals by KeifeRx

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Under the agreement, KeifeRx will develop novel TKI chemical entities for treating neurodegenerative, neuroinflammatory, and mast cell-associated diseases, including KFRX03 and KFRX04.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 01, 2024

                          Lead Product(s) : KFRX03

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Recipient : Georgetown University

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Proceeds from the financing will advance pipeline of optimized, low dose, orally delivered tyrosine kinase inhibitors including Nilotinib BE for the treatment of multiple neurodegenerative diseases.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 12, 2021

                          Lead Product(s) : Nilotinib

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : $6.0 million

                          Deal Type : Series A Financing

                          blank